PURPOSE: To compare survival of patients who undergo treatment in protocols versus survival of patients not in protocols. MATERIALS AND METHODS: Records of 81 adult patients with small-cell lung cancer who underwent chemotherapy and radiation therapy in 1987-1992 were reviewed retrospectively. Forty-one patients were in a protocol; 40 patients were not. Patient demographics and prognostic factors were not statistically significantly different. RESULTS: Median overall survival was 16.7 months in the nonprotocol group versus 29.0 months in the protocol group (P = .0023). Median disease-specific survival was 18.3 months in the nonprotocol group versus 27.1 months in the protocol group (P = .0176). Survival was not statistically significantly influenced by Karnofsky performance status, weight loss, or thoracic radiation dose. CONCLUSION: There was a highly statistically significant difference in survival outcome in the nonprotocol group versus the protocol group (P = .0023). Differences in chemotherapy-radiation therapy timing and other treatment-related factors may have contributed substantially to the improved survival in the protocol group.
PURPOSE: To compare survival of patients who undergo treatment in protocols versus survival of patients not in protocols. MATERIALS AND METHODS: Records of 81 adult patients with small-cell lung cancer who underwent chemotherapy and radiation therapy in 1987-1992 were reviewed retrospectively. Forty-one patients were in a protocol; 40 patients were not. Patient demographics and prognostic factors were not statistically significantly different. RESULTS: Median overall survival was 16.7 months in the nonprotocol group versus 29.0 months in the protocol group (P = .0023). Median disease-specific survival was 18.3 months in the nonprotocol group versus 27.1 months in the protocol group (P = .0176). Survival was not statistically significantly influenced by Karnofsky performance status, weight loss, or thoracic radiation dose. CONCLUSION: There was a highly statistically significant difference in survival outcome in the nonprotocol group versus the protocol group (P = .0023). Differences in chemotherapy-radiation therapy timing and other treatment-related factors may have contributed substantially to the improved survival in the protocol group.
Authors: Christopher J Chow; Elizabeth B Habermann; Anasooya Abraham; Yanrong Zhu; Selwyn M Vickers; David A Rothenberger; Waddah B Al-Refaie Journal: J Am Coll Surg Date: 2013-02-13 Impact factor: 6.113
Authors: Taher Abu-Hejleh; Elizabeth A Chrischilles; Thorvardur R Halfdanarson; Christian Simon; Jane F Pendergast; Dingfeng Jiang; Carmen J Smith; Aaron T Porter; Knute D Carter; Robert B Wallace Journal: Am J Clin Oncol Date: 2016-04 Impact factor: 2.339
Authors: Joseph M Unger; William E Barlow; Diane P Martin; Scott D Ramsey; Michael Leblanc; Ruth Etzioni; Dawn L Hershman Journal: J Natl Cancer Inst Date: 2014-03-13 Impact factor: 13.506
Authors: Yanyan Lou; Bhagirathbhai Dholaria; Aixa Soyano; David Hodge; Jordan Cochuyt; Rami Manochakian; Stephen J Ko; Mathew Thomas; Margaret M Johnson; Neal M Patel; Robert C Miller; Alex A Adjei; Sikander Ailawadhi Journal: Cancer Med Date: 2018-09-02 Impact factor: 4.452